BioMarin survey shows strong Vimizim demand, says Leerink Leerink said its survey of 14 physicians indicates "robust" demand and early commercial adoption of BioMarin's Vimizim. The firm believes physicians and patients are less critical of Vimizim's clinical profile than Wall Street. It reiterates an Outperform rating on BioMarin shares with a $90 price target.
News For BMRN From The Last 14 Days
Check below for free stories on BMRN the last two weeks.